Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INVITAE CORPORATION

(NVTA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Invitae : Wells Fargo Adjusts Invitae's Price Target to to $35 From $30, Keeps Equal-Weight Rating

06/21/2021 | 06:51am EDT


© MT Newswires 2021
All news about INVITAE CORPORATION
10/22INVITAE : UCL and the Francis Crick Institute Announce New Data From TRACERx Research Coll..
PR
10/22Invitae, UCL and the Francis Crick Institute Announce New Data From TRACERx Research Co..
CI
09/25INVITAE : New Study Highlights the Value of Genetic Testing to Guide Clinical Management a..
PR
09/24INSIDER SELL : Invitae
MT
09/09VC DAILY : Digital Health Is Booming, but VC Doesn't See a Bubble Forming
DJ
09/07INVITAE : Ciitizen Announcement Conference Call Presentation
PU
09/07INVITAE : — Combination to bring together the power of genomic and clinical informati..
PU
09/07INVITAE CORP : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Eve..
AQ
09/07INVITAE : to Acquire Consumer Health Tech Company Ciitizen in $325 Million Deal
MT
09/07INVITAE : to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to ..
PR
More news
Analyst Recommendations on INVITAE CORPORATION
More recommendations
Financials (USD)
Sales 2021 484 M - -
Net income 2021 -523 M - -
Net Debt 2021 342 M - -
P/E ratio 2021 -11,0x
Yield 2021 -
Capitalization 6 083 M 6 083 M -
EV / Sales 2021 13,3x
EV / Sales 2022 9,59x
Nbr of Employees 2 600
Free-Float 96,9%
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | NVTA | US46185L1035 | MarketScreener
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 27,99 $
Average target price 40,44 $
Spread / Average Target 44,5%
EPS Revisions
Managers and Directors
Sean Emerson George Chairman, President & Chief Executive Officer
Roxi Wen Chief Financial Officer
Robert Nussbaum Chief Medical Officer
Eric Olivares Chief Science Officer
Layton Wedgeworth Chief Technology Officer
Sector and Competitors